What if

you could be at the forefront of cancer detection

Cancer screening is changing

For a long time we’ve known there’s no training, practice, or test run with cancer. There’s no Let’s get back to that later.”

But today, there are still only a few routine recommended cancer screenings.1 It’s time to shift from screening only for individual cancers to also screening for multiple cancers. 

Join us in not only impacting lives, but in our shared goal of defining the future of patient-first cancer care.

~70% of cancer deaths are caused by cancers without recommended screenings2,3

In order to provide earlier cancer care to more patients, we need to confront today’s challenge: routine screenings fail to detect the majority of invasive cancers.4 These cancers can go undetected until they have progressed to an advanced stage where outcomes are often poor and treatment costs are high.5 – 8


Higher 5-year cancer-specific mortality rate when cancer is detected late Higher 5-year cancer-specific mortality rate when cancer is detected late

Introducing the Galleri® test

The Galleri test is a groundbreaking and potentially life-changing advancement in cancer detection for adults with an elevated risk for cancer, such as those aged 50 or older.

With the ability to detect multiple cancers and the potential to shift cancer detection to earlier stages (based on modeled data),10 the Galleri test aims to change how we think about the future of cancer screening.

All it takes is a simple blood draw.



Early Cancer
Detection

Detects more than 50 types of cancer, with a low false-positive rate, allowing for earlier treatment11,12

Actionable
Results

Predicts where in the body the cancer is located with high accuracy, helping guide next steps to diagnosis11

Testing
With Ease

Can be easily
incorporated into a
routine healthcare visit

Performance supported by large clinical studies

The Galleri test’s performance is supported by rigorous clinical studies with more than 20,000 participants representing diverse populations.11,13,14

20,000+

participants

A comprehensive test experience

GRAIL and its knowledgeable support services help provide a strong foundation in multi-cancer early detection. In the event of a positive result, we can help provide you with clinical resources and materials to support the diagnostic next steps. Plus, you’re always provided with a dedicated team at GRAIL to help support integration into your health system.

1

Test ordered
by healthcare provider

2

Blood drawn
at provider office or lab

3

Results returned
to provider within 10 business days after specimen return 

Galleri supports the values of your health system

We are experts in implementing complex partnerships that align with your health system’s goals.

Population Health

Provides an opportunity to improve screening adherence

Innovation

Differentiates and positions your health system to attract new patients

High-quality Healthcare

Reinforces a focus on quality, helping to strengthen your health system’s reputation


Galleri Health System Patient Survey market research, data on file 2021. Study demographics included 1,001 respondents, age 50+, including high-risk individuals age 35 – 49 (n=150). Respondents had private or commercial health insurance, Medicare, or government insurance coverage and had visited a PCP in the past two years.

Contact us to learn more

Let’s discuss how your health system can be on the forefront of early cancer detection.

The Galleri test is only available in the United States.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
thank-you-message-icon

Thank you

Please check your inbox. You must confirm your subscription to receive emails for the Galleri test.

Important Safety Information

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of Cancer Signal Not Detected” does not rule out cancer. A test result of Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer. 

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. 

Rx only.

Laboratory / Test Information

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

  1. Screening includes methods recommended by United States Preventive Services Task Force (USPSTF) A, B, and C ratings)
  2. Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cancer cases (based on estimated
    proportion of lung cancers that occur in screen-eligible individuals older than 40 years)
  3. Estimated deaths per year in 2021 from American Cancer Society Cancer Facts and Figures 2021. http://www.cancer.org/content/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf
  4. Screening includes methods with USPSTF A or B rating. SEER*Stat Database: Incidence — SEER 18 Regs Research Data, Nov 2017 Sub. Includes
    persons aged 50+ diagnosed 2006 – 2015.
  5. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence — SEER 18 Regs Research
    Data, Nov 2018 Sub. Includes persons aged 50 – 79 diagnosed 2006 – 2015. Early/​Localized” includes invasive localized tumors that have not
    spread beyond organ of origin. Late/​Distant Metastases” includes invasive cancers that have metastasized beyond the organ of origin to other
    parts of the body.
  6. Based on stage II and stage IV breast, colorectal, and lung cancer, and metastatic/non-metastatic pancreatic cancer.
  7. Banegas MP, Yabroff KR, O’Keeffe-Rosetti MC, et al. Medical Care Costs Associated With Cancer in Integrated Delivery Systems. J Natl Compr
    Canc Netw. 2018;16(4):402 – 10.
  8. DaCosta Byfield S, Nash Smyth E, Mytelka D, et al. Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer
    patients in a managed care population. J Med Econ. 2013;16(12):1379 – 86.
  9. Based on 5‑year cancer-specific survival rates. Source: Surveillance, Epidemiology, and End Results (SEER) Program
    (www.seer.cancer.gov) SEER*Stat Database: Incidence — SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50 – 79
    diagnosed 2006 – 2015 Early/​Localized” includes invasive localized tumors that have not spread beyond organ of origin,
    Late/​Metastasized” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.)
  10. Hubbell E, et al. Cancer Epidemiol Biomarkers Prev. 2021;30(3):460 – 468. doi:10.1158/1055 – 9965 .EPI-20 – 1134.
  11. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent
    validation set. Ann Oncol. Jun 24, 2021. doi: 10.1016/j.annonc.2021.05.806
  12. The Galleri test does not detect all cancers and should be used in addition to, and not instead of, routine cancer screening tests recommended by
    clinical guideline organizations such as the American Cancer Society or the US Preventive Services Task Force (USPSTF).
  13. The Circulating Cell-Free Genome Atlas (CCGA) Study was a prospective, multi-center, case-control, observational study with longitudinal follow-up (overall population N=15,254).
  14. The PATHFINDER study is a prospective, multi-center study to evaluate the implementation of the Galleri test into clinical practice. A total of
    6,662 participants without clinical suspicion of cancer have been enrolled with results returned to a study investigator. The study included men
    and women 50 – 79 years of age with and without a history of cancer.